GlassScriptPhysician profile
Susan Jane Ripper
NPI 1649569658
$16,646.96
in general payments reported to CMS, 2019-2025
28 companies · $4,518 in 2025
The $4,518 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,858 · 2020: $933 · 2021: $1,548 · 2022: $2,126 · 2023: $2,722 · 2024: $2,941 · 2025: $4,518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,965 · Education: $217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,964.59 |
| Education | $217.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,427.80 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $2,871.68 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,105.58 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $1,063.46 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $757.38 | 2019-2025 | |
| Gilead Sciences, INC. | $678.08 | 2019-2025 | Livdelzi |
| Braintree Laboratories, INC. | $524.44 | 2019-2025 | Sutab, Suflave |
| Celltrion USA INC. | $524.27 | 2023-2025 | Vegzelma, Yuflyma, Zymfentra |
| Lilly USA, LLC | $404.63 | 2024-2025 | Omvoh |
| Celgene Corporation | $229.10 | 2021-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $222.52 | 2024-2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $206.53 | 2022-2023 | |
| Allergan, INC. | $169.60 | 2019 | |
| Madrigal Pharmaceuticals | $166.52 | 2024-2025 | Rezdiffra, Resmetirom |
| Merck Sharp & Dohme LLC | $151.00 | 2019-2024 | Dificid |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $139.70 | 2019-2021 | |
| Genzyme Corporation | $139.47 | 2022-2024 | |
| Phathom Pharmaceuticals, INC. | $122.64 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $121.54 | 2023-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $118.23 | 2019-2024 | |
| Ardelyx, INC. | $111.07 | 2025 | Ibsrela |
| Fresenius Kabi USA, LLC | $97.41 | 2023-2024 | Idacio |
| Ironwood Pharmaceuticals, INC | $85.49 | 2021-2024 | Linzess |
| Novo Nordisk INC | $59.36 | 2025 | Wegovy |
| Ucb, INC. | $54.81 | 2019 | |
| Redhill Biopharma INC. | $40.94 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.71 | 2023 | Cyltezo |
| Daiichi Sankyo INC. | $24.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Ripper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.